Pricing Log in Create free account

AIM ImmunoTech Inc. (AIM) vs Skye Bioscience, Inc. (SKYE)

AIM ImmunoTech Inc. and Skye Bioscience, Inc. are both Biotechnology companies. AIM ImmunoTech Inc. and Skye Bioscience, Inc. are of similar size ($7.0M and $6.8M). Skye Bioscience, Inc. has the higher net margin (0.00% vs −15,021.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Skye Bioscience, Inc. leads on 9 and AIM ImmunoTech Inc. on 4.

Valuation

Metric AIM SKYE Biotechnology median
P/E n/m n/m 8.50
P/S 30.63 25.76 9.71
P/B 0.38 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.69 n/m 0.64
EV/Sales (69.58) 12.92 9.21
Earnings yield (1,718.41%) (655.48%) (33.15%)
Free cash flow yield (502.43%) (497.63%) (25.50%)

Profitability

Metric AIM SKYE Biotechnology median
Gross margin (23.16%) 68.04% 65.16%
Operating margin (11,724.21%) 0.00% 0.00%
Net margin (15,021.05%) 0.00% 0.00%
Free cash flow margin (15,385.26%) 0.00% 0.00%
Return on equity (2,382.30%) (233.87%) (56.36%)
Return on assets (169.28%) (159.80%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AIM SKYE Biotechnology median
Revenue growth (TTM) (21.49%) — 6.02%
EPS growth (last fiscal year) 72.19% (93.15%) 30.26%
Revenue growth, 5-year CAGR (11.60%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AIM SKYE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.11 0.95 4.72
Net debt to EBITDA 0.22 0.45 0.96

Dividend

Metric AIM SKYE Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric AIM SKYE Biotechnology median
Market cap 6.79m 7.04m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack